CompletedPhase 3NCT00078949
Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- NCIC Clinical Trials Group
- Principal Investigator
- Michael R. Crump, MD, FRCPCPrincess Margaret Hospital, Canada
- Intervention
- rituximab(biological)
- Enrollment
- 849 enrolled
- Eligibility
- 16-65 years · All sexes
- Timeline
- 2003 – 2018
Study locations (27)
- Rush-Presbyterian-St. Luke's Medical Centre, Chicago, Illinois, United States
- Indiana University Medical Center, Indianapolis, Indiana, United States
- Hackensack University Medical Center, Hackensack, New Jersey, United States
- University of Cincinnati, Barrett Cancer Centre, Cincinnati, Ohio, United States
- University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
- The Queen Elizabeth Hospital, Woodville, South Australia, Australia
- Tom Baker Cancer Centre, Calgary, Alberta, Canada
- Cross Cancer Institute, Edmonton, Alberta, Canada
- CancerCare Manitoba, Winnipeg, Manitoba, Canada
- The Moncton Hospital, Moncton, New Brunswick, Canada
- Dr. H. Bliss Murphy Cancer Centre, St. John's, Newfoundland and Labrador, Canada
- QEII Health Sciences Center, Halifax, Nova Scotia, Canada
- Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
- Cancer Centre of Southeastern Ontario at Kingston, Kingston, Ontario, Canada
- London Regional Cancer Program, London, Ontario, Canada
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00078949 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha